Show simple item record

dc.contributor.authorHe, Michelle J.
dc.contributor.authorPu, Wenjun
dc.contributor.authorWang, Xi
dc.contributor.authorZhong, Xiaoni
dc.contributor.authorZhao, Dong
dc.contributor.authorZeng, Zhipeng
dc.contributor.authorCai, Wanxia
dc.contributor.authorLiu, Jiayi
dc.contributor.authorHuang, Jianrong
dc.contributor.authorTang, Donge
dc.contributor.authorDai, Yong
dc.date.accessioned2022-11-28T15:28:16Z
dc.date.available2022-11-28T15:28:16Z
dc.date.issued2022-11-24
dc.identifier.urihttps://hdl.handle.net/1721.1/146630
dc.description.abstractAbstract Background Hepatocellular carcinoma (HCC) is one of the deadliest cancers and is mainly developed from chronic liver diseases such as hepatitis-B infection-associated liver cirrhosis (LC). The progression from LC to HCC makes the detection of diagnostic biomarkers to be challenging. Hence, there have been constant efforts to improve on identifying the critical and predictive changes accompanying the disease progression. Methods In this study, we looked to using the mass spectrometry mediated spatial metabolomics technique to simultaneous examine hundreds of metabolites in an untargeted fashion. Additionally, metabolic profiles were compared between six subregions within the HCC tissue to collect spatial information. Results Through those metabolites, altered metabolic pathways in LC and HCC were identified. Specifically, the amino acid metabolisms and the glycerophospholipid metabolisms experienced the most changes. Many of the altered metabolites and metabolic pathways were able to be connected through the urea cycle. Conclusions The identification of the key metabolites and pathways can expand our knowledge on HCC metabolic reprogramming and help us exam potential biomarkers for earlier detection of the malignant disease progression.en_US
dc.publisherBioMed Centralen_US
dc.relation.isversionofhttps://doi.org/10.1186/s12935-022-02775-9en_US
dc.rightsCreative Commons Attributionen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.sourceBioMed Centralen_US
dc.titleSpatial metabolomics on liver cirrhosis to hepatocellular carcinoma progressionen_US
dc.typeArticleen_US
dc.identifier.citationCancer Cell International. 2022 Nov 24;22(1):366en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biology
dc.contributor.departmentMassachusetts Institute of Technology. Department of Brain and Cognitive Sciences
dc.identifier.mitlicensePUBLISHER_CC
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2022-11-27T04:12:33Z
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dspace.date.submission2022-11-27T04:12:33Z
mit.licensePUBLISHER_CC
mit.metadata.statusAuthority Work and Publication Information Neededen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record